171 related articles for article (PubMed ID: 30818864)
1. Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel.
Khayrani AC; Mahmud H; Oo AKK; Zahra MH; Oze M; Du J; Alam MJ; Afify SM; Quora HAA; Shigehiro T; Calle AS; Okada N; Seno A; Fujita K; Hamada H; Seno Y; Mandai T; Seno M
Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30818864
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer.
Kim JE; Park YJ
Int J Nanomedicine; 2017; 12():645-658. PubMed ID: 28176896
[TBL] [Abstract][Full Text] [Related]
3. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma.
Journo-Gershfeld G; Kapp D; Shamay Y; Kopeček J; David A
Pharm Res; 2012 Apr; 29(4):1121-33. PubMed ID: 22350800
[TBL] [Abstract][Full Text] [Related]
5. Chemokine CCL20 promotes the paclitaxel resistance of CD44
Chen M; Su J; Feng C; Liu Y; Zhao L; Tian Y
Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278466
[TBL] [Abstract][Full Text] [Related]
6. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
[TBL] [Abstract][Full Text] [Related]
7. Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs.
Tang H; Xie Y; Zhu M; Jia J; Liu R; Shen Y; Zheng Y; Guo X; Miao D; Pei J
Int J Nanomedicine; 2022; 17():3013-3041. PubMed ID: 35836838
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.
Auzenne E; Ghosh SC; Khodadadian M; Rivera B; Farquhar D; Price RE; Ravoori M; Kundra V; Freedman RS; Klostergaard J
Neoplasia; 2007 Jun; 9(6):479-86. PubMed ID: 17603630
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
Zhong Y; Goltsche K; Cheng L; Xie F; Meng F; Deng C; Zhong Z; Haag R
Biomaterials; 2016 Apr; 84():250-261. PubMed ID: 26851390
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy.
Edelman R; Assaraf YG; Levitzky I; Shahar T; Livney YD
Oncotarget; 2017 Apr; 8(15):24337-24353. PubMed ID: 28212584
[TBL] [Abstract][Full Text] [Related]
11. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD44-positive ovarian cancers via engineered paclitaxel prodrug nanoparticles for enhanced chemotherapeutic efficacy.
Sun X; Zhao R; Zhao E; Wang Q; Lian W; Xiong J
Biomed Pharmacother; 2022 Oct; 154():113655. PubMed ID: 36942600
[TBL] [Abstract][Full Text] [Related]
13. High paclitaxel-loaded and tumor cell-targeting hyaluronan-coated nanoemulsions.
Kim JE; Park YJ
Colloids Surf B Biointerfaces; 2017 Feb; 150():362-372. PubMed ID: 27823852
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
Wang L; Jia E
Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
[TBL] [Abstract][Full Text] [Related]
15. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
16. Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells.
Mine T; Matsueda S; Gao H; Li Y; Wong KK; Peoples GE; Ferrone S; Ioannides CG
Oncol Rep; 2010 Jun; 23(6):1537-43. PubMed ID: 20428807
[TBL] [Abstract][Full Text] [Related]
17. CD44-Targeted Polymer-Paclitaxel Conjugates to Control the Spread and Growth of Metastatic Tumors.
Zaiden M; Rütter M; Shpirt L; Ventura Y; Feinshtein V; David A
Mol Pharm; 2018 Sep; 15(9):3690-3699. PubMed ID: 29957956
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
19. Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers.
Chen FQ; Zhang JM; Fang XF; Yu H; Liu YL; Li H; Wang YT; Chen MW
Acta Pharmacol Sin; 2017 Jun; 38(6):859-873. PubMed ID: 28260803
[TBL] [Abstract][Full Text] [Related]
20. A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer.
Xie Y; Ren Z; Chen H; Tang H; Zhu M; Lv Z; Bao H; Zhang Y; Liu R; Shen Y; Zheng Y; Miao D; Guo X; Chen H; Wang S; Pei J
Biomed Pharmacother; 2023 Apr; 160():114304. PubMed ID: 36724638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
